Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

February 15, 2024

NASDAQ US Health Care Biotechnology earnings 58 min

Earnings Call Speaker Segments

Chris Taylor

executive
#1

Thanks, operator. Hello, everyone, and good morning. We're glad you could join the Agios conference call and webcast, where we'll go over our financial results for the fourth quarter and the full year 2023, along with recent business highlights. Slides for today's call can be found in the Investors section of our website, agios.com. With me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer. Before we begin, please note that certain statements made today will be forward-looking. Actual events and results may differ materially from those expressed or implied by any forward-looking statements due to various risks, uncertainties and other factors, including those described in our most recent filings with the SEC and any other future filings we may make with the SEC. With that, I'll hand things over to Brian.

Brian Goff

executive
#2

Thanks, Chris, and good morning to all of you, and I appreciate you being here with us. At Agios, our mission involves creating and bringing to patients transformative medicines that lift up and prolong the lives of those dealing with rare diseases. With that aim driving us, we keep producing steady, persuasive results throughout our leading PK activator franchise, and thanks to smooth collaboration across functions within the Agios team, we achieved exceptional strides in pushing this mission forward during 2023. As evidence of that momentum, we shared 3 important data readouts over the past 12 months. In June, we announced favorable top line results from the Phase II portion of the RISE UP trial of mitapivat, our foremost PK activator for sickle cell disease, and then presented the complete data set in December at ASH. Even with recent advances in the sickle cell disease field, no novel oral treatments exist that simultaneously enhance anemia and lower sickle cell pain crises, and that is exactly what we intend to provide through mitapivat. In November, we shared favorable results from the open-label Phase IIa trial of our second PK activator, AG-946, in lower-risk MDS, where 40% of patients reached the transfusion independence endpoint. And only last month, we announced favorable results from the Phase III energized trial of mitapivat in non-transfusion-dependent thalassemia. As a reminder, nontransfusion-dependent, or NTD, thalassemia makes up roughly 2/3 of thalassemia cases in the U.S. and lacks any FDA-approved treatment option. Even though they don't need routine transfusions, NTD thalassemia patients face a major toll on quality of life, a broad array of severe morbidities, and a heightened chance of premature death. Taken together, the steady data produced throughout the mitapivat development program strengthens our confidence in the likelihood of success for our ongoing trials, such as 2 further Phase III readouts anticipated by the close of this year, and these findings underscore how our PK activators could alter the trajectory of numerous hematologic diseases. Sarah will give more specifics on our progress and forthcoming milestones throughout our pipeline in just a few minutes. Crucially, we think our PK activation pipeline stands in a strong position, with several near-term catalysts, to grow into a multibillion-dollar franchise and generate considerable value. While we push forward the late-stage mitapivat development program across various indications, our commercial team is intensely focused on constructing the infrastructure set up via our existing launch in PK deficiency to get ready for possible U.S. launches of mitapivat in thalassemia during 2025, and in sickle cell disease during 2026. Sarah will offer greater specifics on the commercial possibilities for mitapivat in thalassemia, plus an update on our existing launch in PK deficiency, in just a bit. Lastly, as Cecilia will tell you, we closed out 2023 in a robust cash position, holding about $806 million in cash and investments on the balance sheet. Moreover, we keep monitoring Servier's advancement toward possible FDA approval of vorasidenib, given the economics we retain for both the milestone and royalties. At Agios, we're in a genuinely thrilling period, with 4 more Phase III data readouts and 2 possible launches coming up ahead. We're eager for the many chances to generate substantial near-term value for patients, caregivers and shareholders; having said that, I'll hand the call over to Sarah now.

Sarah Gheuens

executive
#3

Thanks, Brian. During 2023, the R&D team at our company achieved enormous strides in moving the PK activator development program forward. Mitapivat sits at the center of what we're doing. It's the PK activator furthest along anywhere in the field, and it has now accumulated over eight years of use in the clinic. The data we've generated in PK deficiency, thalassemia, and sickle cell disease have come in consistently and convincingly, and that reduces the risk attached to the programs we're currently running while also showing how much this molecule might change how patients function day to day and how they feel about their lives. We feel the same enthusiasm about the potential of the broader pipeline we're building out. On top of that, we're glad to say our timelines remain intact, and among the milestones ahead are enrolling the first participants in the Phase IIb study of AG-946 in lower-risk MDS, plus the same step in the Phase I study of AG-181, which is what we call our PAH stabilizer being developed for phenylketonuria. This also involves sharing topline results from the Phase III ACTIVATE-kidsT trial, which is being conducted in regularly transfused pediatric patients who have PK deficiency, and completing patient enrollment for the Phase III ACTIVATE-kids study, also in pediatric patients with PKD. Turning to sickle cell disease, we were pleased to present detailed positive findings at ASH in December from the Phase II portion of the Phase II/III RISE UP study of mitapivat. The trial met its primary endpoint for hemoglobin response, and beyond that, a reduction in the annualized rate of sickle cell pain crisis was observed. The excitement among the investigators has been wonderful. Enrollment continues to move ahead in the Phase III segment of this trial, and we remain on track to finish bringing patients in by the end of this year. Even as the way sickle cell disease is treated continues to evolve, there is still a pressing and unmet demand for oral treatment choices that are novel and easy to use, addressing both anemia and sickle cell gene crisis, and we strongly believe mitapivat could deliver a best-in-class option for people living with this devastating disease. Finally, regarding thalassemia, I want to briefly highlight several important aspects of our program, as well as the favorable top line Phase III results we shared last month in nontransfusion-dependent thalassemia. Just to recap, our Phase III initiative for PYRUKYND in thalassemia — which includes two randomized, placebo-controlled Phase III studies — was built to generate results covering every thalassemia population, including alpha and beta thalassemia as well as groups with varying transfusion requirements. Patients with alpha or beta thalassemia were enrolled in both studies, though the populations differed when it came to transfusion needs. It's worth pointing out that ENERGIZE stands as the first clinical program to include individuals who weren't receiving transfusions on a regular basis, along with alpha thalassemia patients. And as Brian noted, no FDA-approved options exist for non-transfusion-dependent thalassemia, a group that accounts for roughly 2/3 of all thalassemia patients in the U.S. For the people dealing with this condition, life is difficult, they face frequent severe health complications such as blood clots, and they die too young. So it was a real highlight for us to share favorable findings from ENERGIZE. As a quick refresher, the ENERGIZE trial ultimately enrolled 194 individuals suffering from either the alpha or beta form of nontransfusion-dependent thalassemia. Participants were assigned by randomization in a 2:1 ratio, getting either mitapivat at 100 milligrams or a placebo, taken two times per day. How quickly people signed up, how many actually took part in the trial, and the high rates of finishing and continuing on all point to one conclusion: those who aren't receiving routine transfusions were motivated to do something — which speaks to the unmet need this group faces. In this trial, the main goal was hemoglobin response rate, meaning a rise of 1 gram per deciliter or more in average hemoglobin concentration between week 12 and week 24 relative to where patients started. For this trial's key secondary goals, the measures were the shift from baseline in the average FACIT-Fatigue score and the shift from baseline in average hemoglobin concentration, and each was also evaluated between week 12 and week 24. As for the primary endpoint, treatment with mitapivat produced a result that was highly statistically significant: a hemoglobin response was seen in 42.3% of patients in the treatment arm, compared with 1.6% in the placebo arm. Given mitapivat's novel mechanism of action, which is focused on red blood cell health overall, along with the data that has been generated for mitapivat in other disease areas, the benefits observed with mitapivat in this study extended past hemoglobin by itself. To put a finer point on it, when patients received mitapivat at a dose of 100 milligrams, we saw statistically significant gains on both of the key secondary endpoints. One of those was the shift from baseline in the average FACIT-Fatigue score, which is a patient-reported measure that matters a great deal because it captures how people feel and how they function. And importantly, when we look across the primary endpoint and the secondary endpoints, every one of the prespecified subgroup analyses came out in favor of mitapivat over placebo. That tells us the results weren't being driven by any one subgroup, and it backs up our plan to seek a broad label that covers all thalassemia subtypes. So this is the first drug that does more than just raise hemoglobin — it actually helps thalassemia patients feel better. That lines up with what we saw in PKD patients, and it's what we're hoping to deliver for sickle cell disease patients too. On top of the short-term wins, where thalassemia patients said they had less fatigue and felt improved early on, the clinicians in the trial and other KOLs see the promise in lowering hemolysis markers over a longer stretch, and the chance to cut down on serious morbidities down the road. We're really eager to share the complete data set at a medical meeting. Setting aside how thrilling this is, the ENERGIZE results themselves — having that readout in hand — make us more confident about what ENERGIZE-T will show. Whether or not someone requires transfusions, thalassemia remains a hemolytic anemia. On top of that, mitapivat's mechanism of action doesn't hinge on transfusion need. In ENERGIZE, we already showed hemolytic anemia improving, with hemoglobin moving in a positive direction; what we're waiting on now is whether ENERGIZE-T can document that same hemolytic anemia improvement through fewer transfusions. Just to recap, ENERGIZE-T's main goal is transfusion reduction response, which means cutting transfused red blood cell units by at least half, along with a drop of 2 units or more in transfused red blood cells, during any 12-week stretch that runs consecutively, all the way through week 48, when measured against baseline. Similar to the ENERGIZE study conducted in non-transfusion-dependent thalassemia, the way the ENERGIZE-T trial is built lets us show clinical meaningfulness through multiple avenues — a lessening of transfusion burden that also encompasses transfusion metrics consistent with what other studies have employed. This study was designed by combining learnings from prior trials with input we received from agencies. A dynamic assessment window is important in our view, since a patient's disease doesn't change. We look forward to the data readout around the middle of the year, and before this year ends we plan to submit one regulatory filing to the FDA covering results from both ENERGIZE and ENERGIZE-T, seeking a label that would give thalassemia patients a convenient, differentiated oral option. Overall, I'm very proud of how much our R&D team accomplished in 2023, and I'm excited to keep that momentum going in 2024. I'll pass the call to Tsveta now.

Tsveta Milanova

executive
#4

Thank you, Sarah. Thalassemia is still a condition where the need for better therapies is high and available choices are scarce. Regardless of whether patients require transfusions, the impact of this illness on their lives is substantial. People living with thalassemia face a greater risk of death than the general public, and outcomes can be considerably poorer for those who are not transfused on a regular basis compared with those who are. As patients grow older, they deal with more mobility problems and a rising number of complications. Adults who have non-transfusion-dependent thalassemia might in fact report a quality of life that is equivalent to or even worse than that of transfusion-dependent individuals. Naturally, this disease burden translates into rising health care costs. To tackle this unmet need, and motivated by encouraging results from the Phase III ENERGIZE trial of mitapivat, our commercial team is getting ready for a possible launch in thalassemia next year, starting in the U.S. Within the U.S., roughly 6,000 adult patients have a thalassemia diagnosis. About 4,000 of them are non-transfusion-dependent and currently have no treatment choices available. The other 2,000 are transfusion dependent and lack any oral treatment option. With mitapivat, we aim to meet the unmet need of every adult living with thalassemia and to become the first approved therapy for all types of the disease. Beyond the data we are producing through the mitapivat clinical development program, we believe 3 key factors could help drive adoption of mitapivat among non-thalassemia patients in the U.S. First, there is close alignment between where these patients live in the U.S. and where they get care. The map on Slide 20 shows fixed patient prevalence overlaid with Agios clinical trial sites and/or centers of excellence marked by the Gold Stars. Second, the diagnosis rate is high, thanks to the availability of newborn screening and well-established ICD-10 codes. A large number of patients receive their diagnosis before adulthood. And finally, as Slide 21 illustrates, patients and providers are concentrated at selected centers. Roughly 50% of all diagnosed patients receive treatment at fewer than 150 affiliated hematology oncology practices in the U.S., which gives us a clear focus for our initial launch. Given these market dynamics and the PYRUKYND target product profile, we believe we are well positioned to offer a potential foundational treatment option for thalassemia patients regardless of subtype. As a result, our team is concentrating on 4 core areas of U.S. launch preparations. First, building on the foundational work already completed. We keep deepening how sophisticated our understanding of the market is. We are carrying out extensive market research and claims data analysis to guide ACP targeting, field sizing and deployment for launch. Second, we will be introducing a disease education campaign aimed at both patients and clinicians, emphasizing the long-term complications and burden of disease across all thalassemia subtypes. Our disease education efforts will also seek to correct the historical perception that non-transfusion-dependent patients are less likely to face the debilitating long-term effects of thalassemia. To back these initiatives, we are setting up capabilities that will allow us to execute our educational efforts through personal and nonpersonal channels. Third, we're going to keep bolstering our commercial abilities by growing our sales force ahead of the thalassemia launch, getting the team to the right size for a broad and rare disease; and finally, alongside those efforts, we're getting our market access group ready to talk with payers about disease safety education before the potential thalassemia launch next year. Our team has achieved success in market access for PK deficiency, and we're eager to see them clear the path in thalassemia 2. Beyond the well-established U.S. thalassemia market, roughly 13,000 patients live in the EU5 and about 70,000 thalassemia patients are in the Gulf region; we intend to capture the full potential of these extra markets through coordinated regulatory filings, which we plan to pursue with partners. All told, we think the potential launch of mitapivat in thalassemia is a major opportunity for Agios, and a step forward, as we gear up for potential back-to-back launches with sickle cell disease in 2023. Now let me give an update on the current launch of PYRUKYND in PK deficiency. During the fourth quarter of 2023, we brought in $7.1 million in net PYRUKYND revenue versus $7.4 million in the prior quarter, and 178 patients in total have completed a prescription enrollment form, with 18 of those in the fourth quarter of 2023, an 11% increase versus the third quarter. That resulted in net 109 patients on therapy, a 9% increase versus the third quarter. Patients on therapy keep coming from a growing and diverse prescriber base of 154 physicians and reflect a broad demographic and disease manifestation range that is consistent with the adult PK deficiency population. We remain encouraged by the persistency of patients on treatment and stay focused on efficiently identifying providers likely to treat patients with PK deficiency. The capabilities we keep building and expanding through the current launch, including efficient targeting analytics, patient awareness and education, and patient access will give us a firm foundation from which we can maximize the potential U.S. launches in thalassemia in 2025 and in sickle cell disease in 2026. As we move through this catalyst-rich period of Phase III data readout for mitapivat, we look forward to dramatically expanding the number of patients we serve; with that, I will turn the call over to Cecilia.

Cecilia Jones

executive
#5

Thank you, Tsveta. You can find our financial results for the fourth quarter of 2023 in the press release that went out this morning, and additional details will be part of our 10-K, which we'll be filing later on today. I'd like to take a minute now to give some background and call out a handful of important items. For the full year 2023, net revenue for PYRUKYND came to $26.8 million, versus $11.7 million in PYRUKYND revenue during 2022. Net PYRUKYND revenue in Q4 2023 reached $7.1 million, which represents a 4% decrease from the third quarter. That decline stemmed from having fewer weeks of inventory available than the level we finished Q3 with, though this was partly offset by favorable gross to net adjustments. As a reminder, we expect inventory to remain at low levels at any point in time, since our distribution network is limited, made up of 1 specialty pharmacy and 1 specialty distributor. Similar to other rare disease launches, gross to net should land in the 10% to 20% range annually. Looking at our earnings so far, and given how ultra-rare this disease is along with the lengthy lead times involved in getting patients started on therapy, our expectation for 2024 remains slow and steady growth with quarter-to-quarter variability, much like what we experienced in 2023. Cost of sales during the fourth quarter totaled $0.6 million. R&D expenses came to $77 million in the fourth quarter and $296 million for the full year 2023, which is $16 million higher than the full year 2022. These shifts reflect higher development costs for mitapivat along with the upfront payments tied to the license agreement with Alnylam, which were offset by lower expenses resulting from changes in our research organization and the sale of our Oncology business to Servier. SG&A expenses reached $35 million in the fourth quarter and $120 million for the full year 2023, which is a $2 million decrease relative to the full year 2022. As a reminder, through the divestiture of our oncology business to Servier, we keep rights to a potential $200 million milestone if vorasidenib gets FDA approval, plus 15% royalties on potential U.S. net sales. Servier has publicly stated its plans to file for approval before the end of 2023, so we're eager to follow their progress. We closed out the year with cash, cash equivalents and marketable securities of roughly $806 million. We believe this balance, along with anticipated product revenue, interest income and the potential vorasidenib milestone, would allow the company to fund operating expenses and capital expenditures through several value-creating milestones and at least into 2026; this guidance excludes cash inflows that might extend our runway past 2026, such as potential royalties or royalty monetization from vorasidenib, commercializing mitapivat outside the U.S. through 1 or more partnerships, or other potential strategic business or financial agreements. We stay focused on creating shareholder value, including by proactively managing our cost base and taking a disciplined approach to cash allocation as we get ready to support potential future launches of PYRUKYND. With more possible milestones ahead that could generate value soon, I believe our solid financial position will let us act from a place of strength as we keep looking for opportunities to benefit shareholders. At this point, I'll hand the call back to Brian so he can give his closing comments.

Brian Goff

executive
#6

Thank you, Cecilia. With 2023 now behind us—a year in which we accomplished a great deal—our attention is fixed on carrying out the remaining 4 Phase III readouts for mitapivat that should arrive within the coming 2 years, starting with the Phase III ENERGIZE-T trial in transfusion-dependent thalassemia around the midpoint of this year. As positive data readouts for mitapivat keep accumulating one after another, our confidence in the likelihood of success that lies ahead only keeps rising. Our position is strong thanks to a differentiated mechanism of action that enhances red blood cell health past hemoglobin increase and lets us go after sizable commercial opportunities carrying substantial value, along with the possibility of 2 further first-in-class and best-in-class indications for PYRUKYND as we work to build a multibillion-dollar franchise in PK activation. As we keep taking steps toward achieving our vision of turning into a leading rare disease company, we will keep working to be responsible stewards of our balance sheet and to assess meaningful opportunities for value creation. Last, I want to express thanks to every one of our employees for their hard work and dedication to our mission of developing and delivering transformative medicines that elevate and extend the lives of patients living with rare diseases, and to all of our partners, including the patients, physicians, caregivers and participants in our clinical development programs; with that, we will now open the call for questions.

Eric Schmidt

analyst
#7

Congratulations on the progress you've been making lately. Perhaps this one's for Sarah, since the upcoming milestone — or actually the next several milestones — could be the ENERGIZE-T study of mitipevant in patients who are transfusion-dependent. Could you give us some sense in advance, or frame things for us, about the primary endpoint? From what I understand, you're evaluating transfusion reductions somewhat differently from the way we're used to seeing with the luspatercept data; so in what ways could that primary endpoint definition shift how we interpret the data, and what might the hurdle turn out to be?

Brian Goff

executive
#8

Great. Eric, many thanks for that question. And just — before Sarah begins, I simply want to say welcome back to Agios' earnings call. So Sarah, would you like to get started?

Sarah Gheuens

executive
#9

Absolutely, I appreciate that question. So yes, our endpoint — the main one we're using — is defined differently from the primary endpoint that luspatercept employs. What we're measuring is a reduction of 50% during any 12-week window — essentially a rolling period across the full 48 weeks when patients are being evaluated. We think that's a better way to gauge how a patient is doing when you're dealing with a disease that changes over time and across a longer duration, and it more accurately captures what patients actually encounter in the real world. We do include endpoints in our secondary set that resemble the luspatercept primary endpoint. As for the hurdles, it truly is a distinct endpoint. The obstacle isn't really different just because you have several assessment windows instead of one fixed point in time. The 50% threshold is obviously greater than 33%. But as I mentioned, since it's any 12-week period, you get additional chances, so to speak. Luspatercept also had this endpoint in their assessment and review. However, since it wasn't prespecified as either a primary or secondary analysis, it didn't end up in the label.

Chris Raymond

analyst
#10

Perhaps a single question regarding the ENERGIZE data we received last month. A handful of inquiries have come our way — from investors — concerning the shift, so to speak, between the Phase II results and the Phase III results. Hemoglobin response showed some degradation. Yet the effects were measured at differing time points by you. I'm aware you folks stated efficacy did not wane as time passed, but could you clarify this discrepancy we observed? Then I have a follow-up.

Sarah Gheuens

executive
#11

Of course. Appreciate the question. The primary endpoint employed in our Phase II truly differed from the one used in Phase III, which means for Phase II, we simply examined patients achieving a hemoglobin response at one time point; whereas for Phase III, duration got incorporated into that endpoint across a longer stretch of time and was assessed at a later time point since this is a chronic disease; thus, from the Phase II standpoint, what you're actually seeking is maintenance across a longer duration. Therefore we averaged hemoglobin across 12 weeks rather than merely that single time point, which is a far easier bar to reach; concerning waning, no waning of our hemoglobin response is seen by us. So mitapivat in this trial acts quite similarly to the way it acted in PKD. Thus once patients demonstrate a response, they usually sustain that response as time goes on. There's invariably a slight fluctuation in hemoglobin as time goes on. Yet on the whole, it remained positive — the line sort of stays horizontal relative to their baseline. So we feel quite confident about the results we have witnessed in ENERGIZE; furthermore, it's more than hemoglobin by itself that we witnessed. An improvement on the FACIT-Fatigue was genuinely seen by us there too, which we consider extraordinarily meaningful since now we're adding to the hemoglobin plus story here. What we witnessed in PKD has now likewise been witnessed in the nontransfusion-dependent thalassemia population, and that keeps adding to this consistent and compelling data story we keep generating.

Chris Raymond

analyst
#12

All right, and perhaps a quick follow-up to what Eric asked regarding the success threshold for ENERGIZE-T. I realize you're referring to various endpoints, so it isn't a direct head-to-head with luspatercept, but when you consider the clear distinction — mitapivat can be taken by mouth while luspatercept cannot — could you speak broadly about how you expect these two agents to exist side by side in the commercial space?

Sarah Gheuens

executive
#13

Certainly. When we look at patients with nontransfusion-dependent thalassemia, there's presently nothing approved for them. That means mitapivat, should we successfully move it through the remaining development phases, would become the option accessible to that nontransfusion-dependent group, and it is taken orally, which represents a tremendous advantage, particularly for those patients since they aren't visiting the clinic so often; and when a medication demands regular clinic appointments, that generally increases the disease burden. Among the transfusion-dependent group, a subcutaneous form of luspatercept does exist for those with transfusion-dependent beta thalassemia. Our study has encompassed every genotype of thalassemia. That marks one distinction. The oral method of delivery matters greatly here, as it permits nearly effortless integration with whatever transfusion timetable adjustments they already follow, rather than adding extra appointments beyond their transfusion plans. From that angle, it's equally crucial to recognize that the two products work through markedly distinct mechanisms, since luspatercept acts as a red blood cell stimulator whereas mitapivat seeks to enhance overall red blood cell health. Consequently, we believe that from this standpoint, they are quite unlike each other.

Brian Goff

executive
#14

Right, and Chris, I'd say that final idea is the one I'd really stress — people are attempting to draw parallels, yet in many respects those comparisons don't hold up, given how fundamentally different the mechanisms are. You're going to hear quite a bit from us on this, because the evidence we keep seeing, very consistently, makes us more confident that the advantages of pyruvate kinase activation truly extend past hemoglobin. So we'll wait for the data. Luckily, the wait isn't long. ENERGIZE-T arrives midyear. Still, beyond oral and those other aspects, hemoglobin included, what stands out most about this mechanism is that at the end of the day, it comes down to red blood cell health.

Danielle Brill

analyst
#15

I've got another question, this one about the powering assumptions for ENERGIZE-T. As Chris mentioned, we're aware it isn't apples-to-apples. Still, if you look at luspatercept, the mean hemoglobin increase comes to roughly 1.5 grams, and on your primary endpoint they hit, I believe, a response rate near 40%. Given that backdrop, what does your internal expectation look like for mitapivat's performance? I also have a follow-up after that.

Sarah Gheuens

executive
#16

Appreciate the question. On the assumptions side, we haven't discussed those publicly, though naturally we've reviewed every program sitting in front of us, and that covers our own internal ones, where for thalassemia we adopted a development approach quite close to the one used for PKD. As for the hemoglobin increase you brought up — from a transfusion-dependent angle, our view is you don't automatically need hemoglobin to rise on top of getting patients to cut down their transfusions. That's genuinely a distinct approach, since when patients receive transfusions, their hemoglobin declines over time. What we're attempting here, essentially, is preventing patients' hemoglobin from falling back to a transfusion trigger, which would set off a transfusion. Once again it boils down to that differing mechanism of action: if you're, say, stimulating red blood cell production, you'll ultimately raise hemoglobin, whereas our aim of keeping red blood cells happier and healthier, and in turn lowering hemolysis, represents an entirely different route to actually steering clear of transfusions.

Danielle Brill

analyst
#17

That's useful, and it sets up my next question nicely. Is there any information you can share about how much mitapivat might lengthen the lifespan of normal red blood cells?

Sarah Gheuens

executive
#18

When you say that, are you referring to red blood cells from healthy volunteers?

Danielle Brill

analyst
#19

For instance, making transfused blood last longer.

Sarah Gheuens

executive
#20

Right, so that's actually really tough to quantify when you're dealing with a transfusion situation, since everything gets blended together. To separate out which red blood cell components or categories are present, you'd need a really specialized study. So at this point, we have no plans to pursue that for the patients in our transfusion-dependent group.

Gregory Renza

analyst
#21

Congratulations on everything you've accomplished. Brian, you definitely address the massive, multibillion-dollar chance that exists involving PK activation along with your portfolio. I'm just wondering whether you could — perhaps expand on that a bit, maybe give us a few of the inputs or assumptions behind how you arrive at that figure, whether that relates to mitapivat and how the indications ramp up, or the wider portfolio? And maybe I'll simply add my second question, which concerns the PK activation landscape — maybe you and Sarah could just talk a bit about how mitapivat differs from the others, particularly < >. Of course, you brought up the lead. You possess the data set. But regarding certain nuances around pan-PK activation or even selectivity, perhaps just clarify for us what sets things apart as the landscape shifts?

Brian Goff

executive
#22

Yes. Thank you, Greg; I'll begin with your first question regarding the multibillion dollar chance, or chances, that I mentioned during my prepared comments, which truly stems from the reality that we're advancing quickly through our pipeline, going from clearly ultrarare with PKD toward progressively bigger prevalent diseases. A number of those diseases, I believe, are well described when it comes to opportunity, sickle cell certainly, where significant interest and considerable therapeutic development attention have existed. And here, we're discussing a shift from 3,000 to 8,000 patients throughout the U.S. and EU5 for PKD, rising to, within the U.S. by itself, 100,000 patients who have sickle cell disease. Yet it goes beyond that. I mean, as we covered earlier today, we had this truly thrilling chance in the relatively near term, with a possible launch next year in thalassemia, which represents a prevalent step-up for the U.S. compared with PKD, sickle cell as I just noted. And then even beyond that, through our other PK activator, AG-946, entering low-risk MDS. The wonderful thing about all of this is that we're heading the right way when it comes to prevalence, and that lets us reach extremely attractive commercial possibilities. It also lets us steer through the proper pricing dynamics down the road; but above all we're quite excited by the reality that as we push our pipeline forward and as we already mentioned, we have 2 back-to-back launch potentials, with thalassemia next year, then sickle cell disease in 2026, and at that point, Sarah, would you like to take the next question?

Sarah Gheuens

executive
#23

Alright, so when it comes to activating PK and how mitapivat differs from certain other PK activators — what we do is stimulate PK, yes, but across various PK isoenzymes. One of them is PKR, which matters for the red blood cell, and then PKM2 also matters, and we're gaining a better grasp of how much this particular isoenzyme counts when it comes to the conditions we're examining. As you're aware — thalassemia, sickle cell disease, MDF — each of these conditions has distinct elements where stimulating PKM2 could play a role. Since it's present in immature red blood cells, and it's also present in product tissues affected by these conditions, we intend to explore this further in clinical work, particularly in sickle cell disease and the kidney, given that we know the kidney is such a vital organ when it comes to sickle cell disease and that a large number of patients deal with kidney disease, and we think PKM2 might offer an extra benefit in that setting. As for how that stacks up against other PK activators, specifically < > this is the drug that was formerly the leading drug; they consistently described it as a PKR selective agent. When it comes to how that carries over to other isoenzymes, they haven't discussed it — they've only emphasized a selectivity message.

Andrea Tan

analyst
#24

This is for Salveen. I have just one question about sickle cell. Broadly speaking, can you talk about how you view PYRUKYND's place within the commercial landscape as it stands today? And after that, could you also address how enrollment is progressing and what kind of feedback you've received from physicians so far?

Brian Goff

executive
#25

Absolutely. Perhaps I'll begin, and then I'll hand things over quickly to Tsveta, after which Sarah can address the enrollment side. What we're fundamentally pursuing in sickle cell disease rests on our belief that mitapivat PYRUKYND could become what we call a foundational therapy. As we've discussed, its mechanism of action is quite distinct and very different from the options that exist today. We grow more confident that the advantages tied to producing healthier red blood cells truly establish it in that role. On top of that, the fact that it's taken orally simply strengthens that possibility. That said, I'll let Tsveta elaborate not only on our thinking around sickle cell disease, but also on the bridge from PKD to thalassemia and afterward to sickle cell.

Tsveta Milanova

executive
#26

Thanks, Brian. I'll begin by discussing sickle cell disease, though as you pointed out, an extremely significant milestone lies ahead of it with the thalassemia launch, which we see as a key moment for expanding our commercial capabilities, delivering on that thalassemia launch, and afterward seizing the opportunity in sickle cell disease. Regarding sickle cell disease, Brian already noted that 100,000 patients in the U.S. have this condition, which represents a considerable increase over our current position with PK deficiency, and it's an illness where diagnosis occurs and the burden is thoroughly understood. Currently, those sickle cell disease patients who are outpatients have quite few therapeutic choices at their disposal — they either raise hemoglobin levels, as is true with a brighter, or they improve DUCs. Drawing on the Phase II data along with the target product profile, we have PYRUKYND ready for launch. Our belief is that PYRUKYND will be extremely well positioned to offer a therapeutic choice that delivers advantages to physicians, to patients, and in the end to various stakeholders too, by raising hemoglobin, lowering usage, and ultimately enhancing how patients feel and function. That would constitute a distinctive value proposition if we manage to achieve such a profile; thus we're tremendously enthusiastic about the opportunity that lies ahead. Yet prior to reaching sickle cell disease, we are, on an opportunistic basis, quite eager to move forward with our launch preparations for thalassemia as well. Following the ENERGIZE data results we observed during the year, we have unquestionably pressed the button and are now energetically getting ready for the thalassemia launch arriving in 2025. Much like sickle cell disease, I believe the thalassemia launch will be substantially differentiated regarding market characteristics relative to PKD, and that should put us in a strong position for PYRUKYND adoption, assuming approval in 2025, including — once more — that these patients receive diagnoses, with 6,000 diagnosed thalassemia patients in the U.S. and a well-established ICD-10 code. A greater concentration among the prescriber base, together with all these factors, gives us confidence in our capacity to commercialize the product and generate adoption at launch; and as with sickle cell disease, there is improved understanding of thalassemia's unmet needs among both transfusion-dependent and nontransfusion-dependent patients alike. So we are gearing up and preparing our commercial organization to launch in thalassemia in 2025, possibly followed by back-to-back launches in sickle cell disease in 2026.

Brian Goff

executive
#27

I was about to say that's a fantastic set, and I believe everyone can feel how thrilled we are regarding what lies ahead of us. And I was going to invite Sarah to share a remark on how RISE UP Phase III is advancing for sickle cell.

Sarah Gheuens

executive
#28

Since we feel just as eager about getting to those launches, our biggest emphasis at present is naturally on enrolling patients in Phase III. Things with the study are unfolding the way we expected them to. Enthusiasm is running high among our own people and, naturally, among the investigators too. So all of it remains on schedule for hitting the milestone we've laid out for this year.

Tessa Romero

analyst
#29

Thanks, and good morning to Brian and the rest of the team. I'd like to touch briefly on the commercial side of PKD. Is your view still that PKD represents a peak opportunity of $200 million to $250 million within the U.S.? If that's the case, how many years do you expect it would take to reach that level? Then for my second question: we're aware that AG-946 is being advanced in lower-risk MDS. However, since there hasn't been any recent update, we were wondering whether you have officially decided to deprioritize the sickle cell disease program. Could you let us know whether that is accurate or not?

Brian Goff

executive
#30

On your second question, actually, that one's easy to answer right away — the answer is no. Nothing related to AG-946 has been pushed down our list of priorities. The possibilities here genuinely excite us, and when the moment is right, we'll share news on how things are advancing — both in our low-risk MDS efforts and in terms of our position regarding sickle cell disease. Cecilia, would you like to weigh in on the first 1.

Cecilia Jones

executive
#31

Yeah, absolutely. That's what you're asking about. So our enthusiasm for the chance in PKD hasn't gone anywhere, and we still anticipate peak sales of $200 million to $225 million in the U.S. Quarter after quarter, we keep moving forward, and we're picking things up, which is also feeding into the capabilities for that launch. Our view is that it will be gradual and consistent, with the patterns from 2023 carrying on over the coming years, though we are holding to our peak of $200 million to $225 million.

Brian Goff

executive
#32

Right. So, regarding PKD, we have discussed this before, but given the extensive commercial background that Tsveta and I both bring from numerous rare disease launches, this particular one is difficult. It poses a real challenge. The condition is ultrarare, it requires a lot of diagnostic effort, and patients take a long time to come through. So taking it slowly and steadily is the correct approach. What keeps inspiring us quarter after quarter is that persistence, which we observed fairly early on when PYRUKYND and PKD were launched; that trait matters greatly when we consider the chronic rare disease launches ahead that we have our eyes on; therefore, we will follow the slow and steady route and we intend to keep expecting that moving forward. However, how PYRUKYND is doing is, in our view, what genuinely places us in a strong position as we get closer to, ENERGIZE — apologies, I keep saying ENERGIZE — as we get closer to thalassemia and then sickle cell after that.

Greg Harrison

analyst
#33

I also wanted to ask a follow-up regarding AG-946. Broadly speaking, how are you approaching development — and the possibility of indications that overlap with mitapivat, if there might be upside, say, in sickle cell as you've talked about, or perhaps thalassemia? And what data would you require from 946 before you'd make that call?

Brian Goff

executive
#34

Sure, I'll kick things off, and then Sarah can add her thoughts. To begin with, Greg, I'm hoping we find ourselves in that situation, with several indications the way we do today with PYRUKYND. A major strength here at Agios is holding what is truly a leading PK activation franchise, since we aren't developing 1 product but 2, and that gives us varying economics and differing pricing dynamics among the indications across those products. Given where our development program stands with AG-946, I believe there's ample room at present for us to shape suitable target product profiles, be it for low-risk MDS or for sickle cell disease. Regarding low-risk MDS, as I suspect people are aware, we reported very encouraging proof of concept just last year from our Phase IIa study, and right now we're working on refining the design so that we can move ahead with Phase IIb. I'm quite pleased with what the team has accomplished. That will be the following step. And as I've said previously, when the timing is right, we'll also share progress on sickle cell disease. Sarah, is there anything you'd like to add?

Sarah Gheuens

executive
#35

At a high level, what you should anticipate from development is this: our approach is always to build trials that serve the requirements of various stakeholders—which is to say, we treat our target product profile with real seriousness. For 946, that remains true. We hold that in high regard, and we fold in—we will be folding in—the patient voice along with regulatory feedback, clearly, too.

Brian Goff

executive
#36

Absolutely. A strong illustration of this can be seen with sickle cell disease — something we at Agios take real pride in, since our engagement with that community has been extensive. Sarah and I actually went to the conference a year ago, where the community honored us with an award recognizing how attentively and considerately we brought sickle cell disease warriors and caregivers into our thinking around trial design, trial recruitment, and ultimately what the commercial profile ought to be. We intend to take that same approach with AG-946.

Divya Rao

analyst
#37

Divya here, filling in for Marc. I've got two follow-ups, really. First, about what Eric asked before — regarding the transfusion-dependent patients, was the gap in the primary endpoint between mitapivat and luspatercept something the regulatory authorities told you to do? Or did that come more from your own internal decision-making? Then my second one relates to how the Phase IIb and MDS are designed. Are you intending to evaluate several dose levels of AG-946? And whatever you can share about the enrollment criteria compared with what < > used in the < > trial would be wonderful.

Sarah Gheuens

executive
#38

Great, thanks so much, Divya. On your first point about the primary endpoint — yes, absolutely, we do. Like I said when answering the earlier question, our development work happens jointly with regulators, so their input matters enormously to us and we work hard to fold that input in as effectively as possible. That's the path that led us to land on the 50% endpoints across a rolling 12-week period interval, and we genuinely think that's a more dynamic endpoint which truly captures what patients face in the real world. This is the kind of thing that's always valuable, and we feel very thankful to have these discussions, since I believe bringing in input from various stakeholders consistently produces stronger design decisions. So that covers the primary endpoint. Now, on your MDS Phase IIb question — yes, the Phase IIb does involve multiple doses that we're testing. We'll be testing doses higher than what we initially planned, simply because our Phase IIa taught us that MDS patients in general show lower exposure to the same quantity of drug compared with other patient populations and with healthy volunteers. So those lessons are being built into our Phase IIb. As for our inclusion criteria — we haven't presented a trial in progress post or anything of that sort yet, but expect the population to look fairly close to how it looked in our Phase IIa; that said, we'll be concentrating on patients who have transfusion burden. It will also be a broad MDS population, exactly as we permitted in IIa; we aren't ruling out populations such as those with specific mutations or similar things.

Brian Goff

executive
#39

Okay, many thanks, Norma. And I appreciate all of you joining us on this call today. We truly value the excellent questions you've raised. As was discussed earlier, everyone on our team firmly believes we can bring breakthrough treatments to patients and create considerable value over the long term for shareholders, and we are eager to connect with each of you again before long. So thank you very much.

Operator

operator
#40

That wraps up the call for today. We appreciate everyone joining us. At this point, you're free to hang up. All of you, enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.